ArticleCureus2024
Mucosal Healing of Gastric Antral Vascular Ectasia (Watermelon Stomach) After Treatment With Azathioprine.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric antral vascular ectasia (GAVE), commonly known as "watermelon stomach," is characterized by parallel red stripes resembling watermelon stripes on endoscopic examination and is an uncommon but significant cause of chronic gastrointestinal bleeding, often associated with systemic diseases such as autoimmune conditions, liver cirrhosis, chronic renal insufficiency, and cardiovascular disease. Various therapeutic approaches have been introduced for GAVE treatment, including medical, endoscopic, and surgical interventions. We report a case of a 60-year-old man with a prior history of GAVE who developed melena and symptomatic severe anemia. Initial esophagogastroduodenoscopy (EGD) demonstrated oozing antral GAVE. The patient required weekly blood transfusions. In this article, we explored the safety and efficacy of azathioprine treatment for GAVE. We administered 100 mg (oral) of azathioprine once daily and evaluated the patient monthly for four months. After two months, the endoscopy examination results showed visible macroscopic improvement, and after four months, the lesions were healed. The healing process was complete with normal mucosa restored. After two months, there wasn't any need for blood transfusions or iron therapy. We present for the first time the endoscopic healing process of GAVE under azathioprine treatment confirming that the cause of GAVE is autoimmune. Further research is needed to optimize therapeutic strategies and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.